Storage and Transport: New USP Chapter for Investigational Drug Products
Recommendation
14-16 May 2025
Two-day training + 1-day Airport tour at Vienna Airport in cooperation with DHL
In the Pharmacopeial Forum 42(4) [Jun-Jul 2016], the General Chapters - Packaging and Distribution Expert Committee of the U.S. Pharmacopeial Concention (USP) proposed a new chapter as an addition to the Good Storage and Distribution Practices for Drug Products chapters [1079]. This new subchapter should focus on investigational drug products (IDPs; investigational medicinal products in Europe, IMPs).
In the introduction, USP acknowledges that IDPs differ from commercial products:
- Small quantities for many different sites
- Less stability data available especially for early phases of clinical trials
- Temperature excursions of a single container "may jeopardize the entire clinical trial outcome"
Another challenge are different distribution requirements for IDPs in various countries. Sponsors should be aware of this.
The key expectations specified in the proposed new chapter are:
- Storage in a safe and secured area at labelled storage conditions
- Segregation for IDPs not or not yet dispensed yet and for IDPs awaiting return to sponsor or contractor
- Site qualification audits need to be performed
- Anticipation and tracking of expiry or re-test extensions (according to different local regulatory requirements)
- Packaging qualifications should be the same as for commercially available drug products
- Consideration of important distribution risk factors (e.g. distance, time, temperature, handoffs, packaging)
- Confirmation that proper steps are taken to ensure IDP supply chain integrity (including checklists for patients)
- Unblinded IDPs should be quarantined
- Comparators should be shipped and stored according their (new) IDP labelling
The draft chapter also gives a detailed example for calculating a rating of shipment risk that can help to identify probability and impact of missteps in the supply chain.
The deadline for comments is September 30, 2016
After registration on the USP Pharmacopeial Forum website the complete drafts can be accessed.
Related GMP News
16.01.2025EMA adds Considerations for Wholesale Distributors and Brokers on suspicious Offers
16.01.2025Swissmed informs about Control Campaign against illegal Trading in Medicinal Products
16.01.2025Two new PICS Documents on Remote Assessments published
16.01.2025The GDP Non-Compliance Reports of 2024 - An Overview
17.12.2024GDP in the US: Pre-posting of USP Chapter <1079.2> on MKT
17.12.2024Romanian Authority Issues further GDP Non-Compliance Report